Margrethe Vestager, an EU Competition Commissioner, delivered a speech on 20 August 2018 at Copenhagen’s NorWHO where she stressed the importance of effective competition law in the development of new treatments and motivating pharmaceutical companies to pursue innovation. To this end, Vestager also discussed excessive pricing, mergers and generic medicines, expressing the Commission’s support for their entry into the market.
One sentence has caught our particular attention, relating to orphan drugs. Vestager said that the Commission had made it clear that in the future, companies wouldn’t necessarily get exclusive rights to sell their product if pharmacies had already had effective alternatives. MAP contacted Ms Vestager’s office for comment.
You can read the full Speech here.